Inovio investors urged to join class action lawsuit by April 7 deadline for potential compensation.

Investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, are reminded of the April 7, 2026 deadline to join a class action lawsuit. The lawsuit alleges that Inovio made false or misleading statements about manufacturing issues and regulatory prospects related to its CELLECTRA device and INO-3107 biologic, which impacted investor losses. Those affected may seek compensation without upfront costs through Rosen Law Firm, which is leading the case. Investors can submit claims or seek lead plaintiff status before the deadline to participate in potential recovery efforts.